HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has ...

Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized small renal masses, supporting its role as a surgery-sparing local ...

New insights into the biology of kidney cancer, including those informed by scientific discoveries that earned a Nobel Prize, have led to advances in treatment and increased survival rates. New ...

Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate ICESECRET, a prospective, multicenter, ...

IceCure Medical’s ProSense® Cryoablation technology shows promise in treating kidney tumors with an 88.7% recurrence-free rate in patients unable to undergo surgery, based on interim results from the ...

Early-stage kidney cancer is often asymptomatic and discovered incidentally through imaging tests for unrelated conditions. Treatment options include partial nephrectomy, radical nephrectomy, ...

Data supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe A total ...

The approach is particularly suited to patients who are not fit for major surgery due to having only one functioning kidney.

“The Nobel Prize in Medicine or Physiology in 2019 was awarded for the discovery of how mammalian cells sense oxygen,” said William Kim, MD, the Rush S. Dickson Distinguished Professor of Medicine at ...

At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of ...